Skip to main content
. 2023 Jul 28;23:704. doi: 10.1186/s12885-023-11179-5

Table 2.

The main characteristics of a qualified study of tissue levels

Author Year Country Cancer type Antibody Survival
analysis
Quan Zhou [39] 2020 China gastric cancer Abcam OS
Supaporn Yangngam [40] 2020 Thailand cholangiocarcinoma R&D OS
Yan Yang [10] 2016 China hepatocellular carcinoma R&D NO
Kirsten D. Mertz [41] 2015 Switzerland colorectal cancer R&D NO
Zewei Wang [42] 2015 China renal cell carcinoma Abcam OS
Wenwei Hu [14] 2016 China gastric cancer Sigma NO
Xiaoguang Tong [44] 2015 China epithelial ovarian cancer Enzo Life Sciences OS
Satoshi Nagaoka [45] 2020 Japan cholangiocarcinoma NA OS
Wenxiu Wang [46] 2020 China hepatocellular carcinoma R&D OS
Dorothee Grama Tzki [47] 2016 Switzerland gliomas R&D OS
Jianfei Zhang [48] 2016 China gliomas Proteintech OS
Yihui Wen [49] 2018 China

head and neck squamous

cell carcinoma

R&D OS
Kazuya Ishikawa [50] 2014 Japan

squamous cell carcinoma

of the tongue

R&D OS
Lu Jing [32] 2020 China hepatocellular carcinoma NA NA
Chen Ling [51] 2020 China non-small cell lung cancer R&D OS
Zhao Lirong [52] 2020 China ovarian cancer NA NA
Xia Bingxiang [38] 2017 China gastric cancer Dako OS
Zhang Jianfei [53] 2016 China gliomas NA NA
Huang Di [54] 2016 China colorectal cancer Abcam OS
Hu Xia [37] 2019 China esophageal adenocarcinoma Proteintech NA
Yue Ying [55] 2018 China

esophageal squamous

cell carcinomas

Abcam OS
Hu Wenwei [56] 2018 China gastric cancer NA NA